HSBC Holdings’s Protalix BioTherapeutics PLX Stock Holding History

HSBC Holdings’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,535	Closed	-$64.3K	–	3197
2025 Q1	$64.3K	Sell	25,535 -14,488	-36%	-$34.6K	﹤0.01%	2876
2024 Q4	$75.6K	Hold	40,023	–	–	﹤0.01%	2933
2024 Q3	$41.2K	Sell	40,023 -7,601	-16%	-$7.99K	﹤0.01%	2901
2024 Q2	$58.1K	Buy	47,624 +944	+2%	+$1.11K	﹤0.01%	2805
2024 Q1	$58.8K	Buy	46,680 +6,614	+17%	+$9.88K	﹤0.01%	2920
2023 Q4	$70.9K	Hold	40,066	–	–	﹤0.01%	2628
2023 Q3	$64.5K	Buy	+40,066	New	+$71.9K	﹤0.01%	2604
2016 Q2	–	Sell	-1,500	Closed	-$13K	–	2134
2016 Q1	$13K	Buy	+1,500	New	+$12.9K	﹤0.01%	2067
2014 Q2	–	Sell	-2,822	Closed	-$129K	–	1791
2014 Q1	$129K	Buy	+2,822	New	+$132K	﹤0.01%	1673

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings's PLX Position: Q2 2025 in Review

HSBC Holdings sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 25,535 shares — an estimated $64.3K sold.

HSBC Holdings first reported a position in PLX in Q1 2014 and held it in 9 quarters. The position peaked at $129K in Q1 2014. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

HSBC Holdings reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
HSBC Holdings sold 25,535 Protalix BioTherapeutics shares in Q2 2025, an estimated $64.3K.
HSBC Holdings first reported a position in Protalix BioTherapeutics in Q1 2014 and held it in 9 quarters.
HSBC Holdings's Protalix BioTherapeutics position peaked at $129K in Q1 2014.
63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.